| VF | 1) Ventricular Fibrillation ? Tx of Ventricular Fibrillation ... |
|---|---|
| Ts | skin temperature; tosylate |
| ACD | absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom... |
| ACD | 1) Absolute Cardiac Dullness; Àý´ë½ÉµÐŹÀ½ 2) Anemia of Chronic Disease &nbs... |
| D/W | Dextrose in Water |
| BT | Bretylium tosylate |
|---|---|
| ACD | Acid citrate dextrose |
| CPD | Citrate-phosphate-dextrose |
| CPDA-1 | Citrate-phosphate-dextrose-adenine |
| PDA | Potato Dextrose Agar |
| bretylium tosylate | <chemical> An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic. Pharmacological action: adrenergic agents, anti-arrhythmia agents, antihypertensive agents, sympatholytics. Chemical name: Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) (12 Dec 1998) |
|---|---|
| bretylium | <drug> An antihypertensive which on chronic oral dosing diminishes the release of norepinephrine from noradrenergic nerve endings. Pharmacologic action: Suppress ventricular fibrillation and ventricular tachycardia, initially releases norepinephrine, then prevents synaptic release of norepinephrine; transiently increases myocardial contractility Uses: Treatment of refractory ventricular fibrillation and pulseless ventricular tachycardia after defibrillation, epinephrine, and lidocaine. Treatment of ventricular tachycardia with a pulse after lidocaine and procainamide. Treatment of wide complex tachycardia of uncertain type after lidocaine and adenosine. Dose: 5 mg/kg IV initially, then 10 mg/kg every 5-10 minutes to a maximum of 30 mg/kg In persistently recurring ventricular tachycardia, load with 5-10 mg/kg diluted in 50 mL and infuse over 8-10 min. Follow with continuous infusion at 1-2 mg/min Onset: Transient hypertension and tachycardia lasts about 20 min. Postural hypotension begins about 20 min after injection and peaks about 60 min later. Potential complications: 1. May cause initial hypertension followed by a decrease in systemic vascular resistance and hypotension. 2. May exacerbate digitalis toxicity Note: Lidocaine is considered the first line drug for ventricular arrhythmias. Bretylium causes more hemodynamic instability than lidocaine and has not been shown to increase survival more than lidocaine. (05 Mar 2000) |
| itramin tosylate | 2-Aminoethyl nitrate p-toluenesulfonate;a vasodilator. (05 Mar 2000) |
| tosylate | USAN-approved contraction for p-toluenesulfonate. (05 Mar 2000) |
| acid-citrate-dextrose | A citrate anticoagulant used for the collection and preservation of whole blood. It has largely been replaced by newer coagulants (CPD, Adsol) that allow for longer shelf life for blood and blood products. Acronym: ACD (05 Mar 2000) |
| potato dextrose agar | A culture medium used extensively for the cultivation of fungi; especially good for development of conidia and other sporulating forms by which an organism is identified microscopically. (05 Mar 2000) |
| Sabouraud's dextrose agar | A dextrose peptone media that supports the growth of most pathogenic fungi. (05 Mar 2000) |
| dextrose | <chemistry> A sirupy, or white crystalline, variety of sugar, C6H12O6 (so called from turning the plane of polarization to the right), occurring in many ripe fruits. Dextrose and levulose are obtained by the inversion of cane sugar or sucrose, and hence called invert sugar. Dextrose is chiefly obtained by the action of heat and acids on starch, and hence called also starch sugar. It is also formed from starchy food by the action of the amylolytic ferments of saliva and pancreatic juice. The solid products are known to the trade as grape sugar; the sirupy products as glucose, or mixing sirup. These are harmless, but are only about half as sweet as cane or sucrose. See: Dexter. Source: Websters Dictionary (01 Mar 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|